Trained Immunity in Health and Disease

Abstract

Trained immunity as a critical regulator of host defense and disease pathogenesis bridges the gap between innate and adaptive immunity. For decades, the classic dichotomy of innate immunity and adaptive immunity has shaped our knowledge of immune function. Innate immunity has traditionally been regarded as a rapid, nonspecific first line of defense without memory capacity, while adaptive immunity is characterized by slower, antigen-specific responses and long-term immune memory. However, emerging evidence that innate immunity exhibits memory-like properties challenges the paradigm. Basically, innate immune cells with nonspecific memory retain functional imprints of prior encounters with diverse stimuli. Here, we comprehensively explore the intricate molecular and cellular mechanisms that underpin trained immunity, encompassing epigenetic inheritance, metabolic reprogramming, and transcriptional rewiring. Its dual roles are highlighted in health and disease. On one hand, it bolsters host defense against a broad spectrum of pathogens from bacteria to viruses, and enhances vaccine efficacy through heterologous protection. On the other hand, its dysregulation contributes to infection, inflammation, and cancer progression. As for the promising opportunities on therapeutic intervention, the challenges in precisely modulating trained immunity are tackled to offer a holistic perspective on the dynamically evolving field.

Keywords

epigenetic inheritance / immunotherapy / immune cells / metabolic reprogramming / trained immunity

References

[1] G. Hajishengallis, M. G. Netea, and T. Chavakis, “Trained Immunity in Chronic Inflammatory Diseases and Cancer,” Nature Reviews Immunology 25, no. 7 (2025): 497-514.

[2] M. Huang, Z. Wu, J. Li, Y. Ding, S. Chen, and X. Li, “Plant Protection Against Viruses: An Integrated Review of Plant Immunity Agents,” International Journal of Molecular Sciences 24, no. 5 (2023): 4453.

[3] M. G. Netea, L. A. Joosten, E. Latz, et al., “Trained Immunity: A Program of Innate Immune Memory in Health and Disease,” Science 352, no. 6284 (2016): aaf1098.

[4] N. Katzmarski, J. Domínguez-Andrés, B. Cirovic, et al., “Transmission of Trained Immunity and Heterologous Resistance to Infections Across Generations,” Nature Immunology 22, no. 11 (2021): 1382-1390.

[5] R. Wang, C. Lan, K. Benlagha, et al., “The Interaction of Innate Immune and Adaptive Immune System,” MedComm 5, no. 10 (2024): e714.

[6] M. G. Netea, J. Quintin, and J. W. van der Meer, “Trained Immunity: A Memory for Innate Host Defense,” Cell Host & Microbe 9, no. 5 (2011): 355-361.

[7] X. Xu, Q. Peng, X. Jiang, et al., “Metabolic Reprogramming and Epigenetic Modifications in Cancer: From the Impacts and Mechanisms to the Treatment Potential,” Experimental & Molecular Medicine 55, no. 7 (2023): 1357-1370.

[8] C. Chen, J. Wang, X. Zhu, et al., “Lactylation as a Metabolic Epigenetic Modification: Mechanistic Insights and Regulatory Pathways From Cells to Organs and Diseases,” Metabolism 169 (2025): 156289.

[9] Q. Hu, Y. Li, D. Li, et al., “Amino Acid Metabolism Regulated by lncRNAs: The Propellant Behind Cancer Metabolic Reprogramming,” Cell Communication and Signaling 21, no. 1 (2023): 87.

[10] J. Domínguez-Andrés, J. C. Dos Santos, S. Bekkering, et al., “Trained Immunity: Adaptation Within Innate Immune Mechanisms,” Physiological Reviews 103, no. 1 (2023): 313-346.

[11] J. Ochando, W. J. M. Mulder, J. C. Madsen, M. G. Netea, and R. Duivenvoorden, “Trained Immunity—basic Concepts and Contributions to Immunopathology,” Nature Reviews Nephrology 19, no. 1 (2023): 23-37.

[12] U. K. Kar and L. A. B. Joosten, “Training the Trainable Cells of the Immune System and Beyond,” Nature Immunology 21, no. 2 (2020): 115-119.

[13] J. G. Cheong, A. Ravishankar, S. Sharma, et al., “Epigenetic Memory of Coronavirus Infection in Innate Immune Cells and Their Progenitors,” Cell 186, no. 18 (2023): 3882-3902. e24.

[14] N. P. Riksen, S. Bekkering, W. J. M. Mulder, and M. G. Netea, “Trained Immunity in Atherosclerotic Cardiovascular Disease,” Nature Reviews Cardiology 20, no. 12 (2023): 799-811.

[15] Y. Chen, M. Yang, W. Huang, et al., “Mitochondrial Metabolic Reprogramming by CD36 Signaling Drives Macrophage Inflammatory Responses,” Circulation Research 125, no. 12 (2019): 1087-1102.

[16] L. Edgar, N. Akbar, A. T. Braithwaite, et al., “Hyperglycemia Induces Trained Immunity in Macrophages and Their Precursors and Promotes Atherosclerosis,” Circulation 144, no. 12 (2021): 961-982.

[17] L. Martín-Cruz and O. Palomares, “Allergen-Specific Immunotherapy and Trained Immunity,” Allergy 80, no. 3 (2025): 677-689.

[18] C. Ding, R. Shrestha, X. Zhu, et al., “Inducing Trained Immunity in Pro-metastatic Macrophages to Control Tumor Metastasis,” Nature Immunology 24, no. 2 (2023): 239-254.

[19] S. Zhang, Z. Cui, D. Zhang, et al., “Nuclear Adenine Activates hnRNPA2B1 to Enhance Antibacterial Innate Immunity,” Cell Metabolism 37, no. 2 (2025): 413-428. e7.

[20] A. M. Marzeda, A. Schwenzer, B. S. Didov, et al., “Investigating Endogenous Immune-mediated Monocyte Memory in Rheumatoid Arthritis,” Annals of the Rheumatic Diseases 84, no. 9 (2025): 1484-1500.

[21] I. Melero, M. de Miguel Luken, G. de Velasco, et al., “Neutralizing GDF-15 Can Overcome Anti-PD-1 and Anti-PD-L1 Resistance in Solid Tumours,” Nature 637, no. 8048 (2025): 1218-1227.

[22] S. Carpenter and L. A. J. O'Neill, “From Periphery to Center Stage: 50 Years of Advancements in Innate Immunity,” Cell 187, no. 9 (2024): 2030-2051.

[23] E. Vivier, L. Rebuffet, E. Narni-Mancinelli, S. Cornen, R. Y. Igarashi, and V. R. Fantin, “Natural Killer Cell Therapies,” Nature 626, no. 8000 (2024): 727-736.

[24] Y. Yao, M. Jeyanathan, S. Haddadi, et al., “Induction of Autonomous Memory Alveolar Macrophages Requires T Cell Help and Is Critical to Trained Immunity,” Cell 175, no. 6 (2018): 1634-1650. e17.

[25] T. Wang, J. Zhang, Y. Wang, et al., “Influenza-trained Mucosal-resident Alveolar Macrophages Confer Long-term Antitumor Immunity in the Lungs,” Nature Immunology 24, no. 3 (2023): 423-438.

[26] L. Kalafati, I. Kourtzelis, J. Schulte-Schrepping, et al., “Innate Immune Training of Granulopoiesis Promotes Anti-tumor Activity,” Cell 183, no. 3 (2020): 771-785. e12.

[27] A. W. Daman, A. C. Antonelli, G. Redelman-Sidi, et al., “Microbial Cancer Immunotherapy Reprograms Hematopoiesis to Enhance Myeloid-driven Anti-tumor Immunity,” Cancer Cell 43, no. 8 (2025): 1442-1459. e10.

[28] S. Saeed, J. Quintin, H. H. Kerstens, et al., “Epigenetic Programming of Monocyte-to-macrophage Differentiation and Trained Innate Immunity,” Science 345, no. 6204 (2014): 1251086.

[29] Z. Dong, L. Hou, W. Luo, et al., “Myocardial Infarction Drives Trained Immunity of Monocytes, Accelerating Atherosclerosis,” European Heart Journal 45, no. 9 (2024): 669-684.

[30] A. Simats, S. Zhang, D. Messerer, et al., “Innate Immune Memory After Brain Injury Drives Inflammatory Cardiac Dysfunction,” Cell 187, no. 17 (2024): 4637-4655. e26.

[31] T. Torcellan, C. Friedrich, R. Doucet-Ladevèze, et al., “Circulating NK Cells Establish Tissue Residency Upon Acute Infection of Skin and Mediate Accelerated Effector Responses to Secondary Infection,” Immunity 57, no. 1 (2024): 124-140. e7.

[32] S. G. Smith, J. Kleinnijenhuis, M. G. Netea, and H. M. Dockrell, “Whole Blood Profiling of Bacillus Calmette-Guérin-Induced Trained Innate Immunity in Infants Identifies Epidermal Growth Factor, IL-6, Platelet-Derived Growth Factor-AB/BB, and Natural Killer Cell Activation,” Frontiers in Immunology 8 (2017): 644.

[33] M. A. Musrati, B. Stijlemans, A. Azouz, et al., “Infection History Imprints Prolonged Changes to the Epigenome, Transcriptome and Function of Kupffer Cells,” Journal of Hepatology 81, no. 6 (2024): 1023-1039.

[34] N. Khan, J. Downey, J. Sanz, et al., “M. tuberculosis Reprograms Hematopoietic Stem Cells to Limit Myelopoiesis and Impair Trained Immunity,” Cell 183, no. 3 (2020): 752-770. e22.

[35] E. Kaufmann, J. Sanz, J. L. Dunn, et al., “BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity Against Tuberculosis,” Cell 172, no. 1-2 (2018): 176-190. e19.

[36] M. Radhouani, A. Farhat, A. Hakobyan, et al., “Eosinophil Innate Immune Memory After Bacterial Skin Infection Promotes Allergic Lung Inflammation,” Science Immunology 10, no. 106 (2025): eadp6231.

[37] S. Naik, S. B. Larsen, N. C. Gomez, et al., “Inflammatory Memory Sensitizes Skin Epithelial Stem Cells to Tissue Damage,” Nature 550, no. 7677 (2017): 475-480.

[38] S. K. Russell, J. K. Harrison, B. S. Olson, et al., “Uropathogenic Escherichia coli Infection-induced Epithelial Trained Immunity Impacts Urinary Tract Disease Outcome,” Nature Microbiology 8, no. 5 (2023): 875-888.

[39] T. S. Mills, B. Kain, M. A. Burchill, et al., “A Distinct Metabolic and Epigenetic state Drives Trained Immunity in HSC-derived Macrophages From Autoimmune Mice,” Cell Stem Cell 31, no. 11 (2024): 1630-1649. e8.

[40] A. Broquet, V. Gourain, T. Goronflot, et al., “Sepsis-trained Macrophages Promote Antitumoral Tissue-resident T Cells,” Nature Immunology 25, no. 5 (2024): 802-819.

[41] E. K. Santosa, H. Kim, T. Rückert, et al., “Control of Nutrient Uptake by IRF4 Orchestrates Innate Immune Memory,” Nature Immunology 24, no. 10 (2023): 1685-1697.

[42] N. Serafini and J. P. Di Santo, “Group 3 Innate Lymphoid Cells: A Trained Gutkeeper,” Immunological Reviews 323, no. 1 (2024): 126-137.

[43] Y. Li, Z. Wang, S. Duan, et al., “TLR4(+)group 2 Innate Lymphoid Cells Contribute to Persistent Type 2 Immunity in Airway Diseases,” Nature Communications 16, no. 1 (2025): 7108.

[44] N. Serafini, A. Jarade, L. Surace, et al., “Trained ILC3 Responses Promote Intestinal Defense,” Science 375, no. 6583 (2022): 859-863.

[45] X. Wang, G. Shi, X. Zhu, et al., “Engineered Bacteria-Nanoparticle Conjugate Reprograms Immunosuppressive Niche via Dendritic Cell-Centric Innate-Adaptive Immune Coupling,” ACS Nano 19, no. 27 (2025): 24938-24953.

[46] M. A. Risha, K. D. Reddy, S. S. P. Nemani, et al., “Epigenetic Training of human Bronchial Epithelium Cells by Repeated Rhinovirus Infections,” Allergy 79, no. 12 (2024): 3385-3400.

[47] B. de Laval, J. Maurizio, P. K. Kandalla, et al., “C/EBPβ-Dependent Epigenetic Memory Induces Trained Immunity in Hematopoietic Stem Cells,” Cell Stem Cell 30, no. 1 (2023): 112.

[48] A. C. Schmidt, L. Fairlie, E. Hellström, et al., “BCG Revaccination for the Prevention of Mycobacterium Tuberculosis Infection,” New England Journal of Medicine 392, no. 18 (2025): 1789-1800.

[49] P. Vuscan, B. Kischkel, L. A. B. Joosten, and M. G. Netea, “Trained Immunity: General and Emerging Concepts,” Immunological Reviews 323, no. 1 (2024): 164-185.

[50] B. Liu, Y. He, X. Wu, et al., “Mapping Putative Enhancers in Mouse Oocytes and Early Embryos Reveals TCF3/12 as Key Folliculogenesis Regulators,” Nature Cell Biology 26, no. 6 (2024): 962-974.

[51] R. J. Röring, P. A. Debisarun, J. Botey-Bataller, et al., “MMR Vaccination Induces Trained Immunity via Functional and Metabolic Reprogramming of Γδ T Cells,” Journal of Clinical Investigation 134, no. 7 (2024): e170848.

[52] F. Wimmers, M. Donato, A. Kuo, et al., “The Single-cell Epigenomic and Transcriptional Landscape of Immunity to Influenza Vaccination,” Cell 184, no. 15 (2021): 3915-3935. e21.

[53] M. H. Fitz-James and G. Cavalli, “Molecular Mechanisms of Transgenerational Epigenetic Inheritance,” Nature Reviews Genetics 23, no. 6 (2022): 325-341.

[54] M. Takata, M. Takahashi, T. Ishibashi, et al., “Transgenerational Epigenetic Effect of Kings' aging on Offspring's Caste Fate Mediated by Sperm DNA Methylation in Termites,” Proceedings of the National Academy of Sciences of the United States of America 122, no. 24 (2025): e2509506122.

[55] L. Zheng, X. Chen, X. He, et al., “METTL4-Mediated Mitochondrial DNA N6-Methyldeoxyadenosine Promoting Macrophage Inflammation and Atherosclerosis,” Circulation 151, no. 13 (2025): 946-965.

[56] F. Lyko, “The DNA Methyltransferase family: A Versatile Toolkit for Epigenetic Regulation,” Nature Reviews Genetics 19, no. 2 (2018): 81-92.

[57] X. Zhang, Y. Zhang, C. Wang, and X. Wang, “TET (Ten-eleven translocation) family Proteins: Structure, Biological Functions and Applications,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 297.

[58] A. Simonis, S. J. Theobald, A. E. Koch, et al., “Persistent Epigenetic Memory of SARS-CoV-2 mRNA Vaccination in Monocyte-derived Macrophages,” Molecular Systems Biology 21, no. 4 (2025): 341-360.

[59] R. Pichler, G. Diem, H. Hackl, et al., “Intravesical BCG in Bladder Cancer Induces Innate Immune Responses Against SARS-CoV-2,” Frontiers in Immunology 14 (2023): 1202157.

[60] D. Ilijazi, W. Pulverer, I. E. Ertl, et al., “Discovery of Molecular DNA Methylation-Based Biomarkers Through Genome-Wide Analysis of Response Patterns to BCG for Bladder Cancer,” Cells 9, no. 8 (2020): 1839.

[61] S. E. Compton, S. M. Kitchen-Goosen, L. M. DeCamp, et al., “LKB1 controls Inflammatory Potential Through CRTC2-dependent Histone Acetylation,” Molecular Cell 83, no. 11 (2023): 1872-1886. e5.

[62] D. Yuan, X. Zhang, Y. Yang, et al., “Schlank Orchestrates Insect Developmental Transition by Switching H3K27 Acetylation to Trimethylation in the Prothoracic Gland,” Proceedings of the National Academy of Sciences of the United States of America 121, no. 35 (2024): e2401861121.

[63] J. Chen, J. H. Hong, Y. Huang, et al., “EZH2 mediated Metabolic Rewiring Promotes Tumor Growth Independently of Histone Methyltransferase Activity in Ovarian Cancer,” Molecular Cancer 22, no. 1 (2023): 85.

[64] S. Ma, M. S. Dahabieh, T. H. Mann, et al., “Nutrient-driven Histone Code Determines Exhausted CD8(+) T Cell Fates,” Science 387, no. 6734 (2025): eadj3020.

[65] Y. Jing, X. Jiang, Q. Ji, et al., “Genome-wide CRISPR Activation Screening in Senescent Cells Reveals SOX5 as a Driver and Therapeutic Target of Rejuvenation,” Cell Stem Cell 30, no. 11 (2023): 1452-1471. e10.

[66] S. Hu, A. Song, L. Peng, et al., “H3K4me2/3 modulate the Stability of RNA Polymerase II Pausing,” Cell Research 33, no. 5 (2023): 403-406.

[67] R. Ostuni, V. Piccolo, I. Barozzi, et al., “Latent Enhancers Activated by Stimulation in Differentiated Cells,” Cell 152, no. 1-2 (2013): 157-171.

[68] J. Domínguez-Andrés, B. Novakovic, Y. Li, et al., “The Itaconate Pathway Is a Central Regulatory Node Linking Innate Immune Tolerance and Trained Immunity,” Cell Metabolism 29, no. 1 (2019): 211-220. e5.

[69] S. C. Cheng, J. Quintin, R. A. Cramer, et al., “mTOR- and HIF-1α-mediated Aerobic Glycolysis as Metabolic Basis for Trained Immunity,” Science 345, no. 6204 (2014): 1250684.

[70] H. Su, Z. Liang, S. Weng, et al., “miR-9-5p Regulates Immunometabolic and Epigenetic Pathways in β-glucan-trained Immunity via IDH3α,” JCI Insight 7, no. 6 (2022): e159640.

[71] A. V. Ferreira, J. C. Alarcon-Barrera, J. Domínguez-Andrés, et al., “Fatty Acid Desaturation and Lipoxygenase Pathways Support Trained Immunity,” Nature Communications 14, no. 1 (2023): 7385.

[72] R. Viurcos-Sanabria, A. N. Manjarrez-Reyna, H. Solleiro-Villavicencio, et al., “In Vitro Exposure of Primary Human T Cells and Monocytes to Polyclonal Stimuli Reveals a Basal Susceptibility to Display an Impaired Cellular Immune Response and Develop Severe COVID-19,” Frontiers in Immunology 13 (2022): 897995.

[73] L. Yang, Z. Chu, M. Liu, et al., “Amino Acid Metabolism in Immune Cells: Essential Regulators of the Effector Functions, and Promising Opportunities to Enhance Cancer Immunotherapy,” Journal of Hematology & Oncology 16, no. 1 (2023): 59.

[74] R. J. Arts, B. Novakovic, R. Ter Horst, et al., “Glutaminolysis and Fumarate Accumulation Integrate Immunometabolic and Epigenetic Programs in Trained Immunity,” Cell Metabolism 24, no. 6 (2016): 807-819.

[75] Y. Wang, W. Shao, X. Liu, et al., “High Recallability of Memory B Cells Requires ZFP318-dependent Transcriptional Regulation of Mitochondrial Function,” Immunity 57, no. 8 (2024): 1848-1863. e7.

[76] R. A. Veitia, “Rethinking Transcription Factor Dynamics and Transcription Regulation in Eukaryotes,” Trends in Biochemical Sciences 50, no. 5 (2025): 376-384.

[77] X. H. Yu, D. W. Zhang, X. L. Zheng, and C. K. Tang, “Itaconate: An Emerging Determinant of Inflammation in Activated Macrophages,” Immunology and Cell Biology 97, no. 2 (2019): 134-141.

[78] H. Wang, W. Li, and S. J. Zheng, “Advances on Innate Immune Evasion by Avian Immunosuppressive Viruses,” Frontiers in Immunology 13 (2022): 901913.

[79] J. Ferrer and N. Dimitrova, “Transcription Regulation by Long Non-coding RNAs: Mechanisms and Disease Relevance,” Nature Reviews Molecular Cell Biology 25, no. 5 (2024): 396-415.

[80] S. Fanucchi, E. T. Fok, E. Dalla, et al., “Immune Genes Are Primed for Robust Transcription by Proximal Long Noncoding RNAs Located in Nuclear Compartments,” Nature Genetics 51, no. 1 (2019): 138-150.

[81] J. Chen, A. Jamaiyar, W. Wu, et al., “Deficiency of lncRNA MERRICAL Abrogates Macrophage Chemotaxis and Diabetes-associated Atherosclerosis,” Cell Reports 43, no. 3 (2024): 113815.

[82] L. Chen, L. Huang, Y. Gu, C. Li, P. Sun, and Y. Xiang, “Novel Post-translational Modifications of Protein by Metabolites With Immune Responses and Immune-related Molecules in Cancer Immunotherapy,” International Journal of Biological Macromolecules 277, no. Pt 1 (2024): 133883.

[83] C. Yu, Y. Chen, H. Luo, et al., “NAT10 promotes Vascular Remodelling via mRNA ac4C Acetylation,” European Heart Journal 46, no. 3 (2025): 288-304.

[84] L. Chen, C. He, Z. Ou, and C. Zhao, “TNF-α Drives Bladder Cancer Metastasis via METTL3-mediated m6A Modification to Promote CLASP2/IQGAP1-dependent Cytoskeleton Remodeling,” Biochimica et Biophysica Acta - Molecular Basis of Disease 1871, no. 5 (2025): 167811.

[85] H. Xie, M. Shi, Y. Liu, et al., “Identification of m6A- and Ferroptosis-related lncRNA Signature for Predicting Immune Efficacy in Hepatocellular Carcinoma,” Frontiers in Immunology 13 (2022): 914977.

[86] X. Nie, B. Ma, L. Liu, et al., “Endoplasmic Reticulum Stress Mediated NLRP3 Inflammasome Activation and Pyroptosis in THP-1 Macrophages Infected With Bacillus Calmette-Guérin,” International Journal of Molecular Sciences 24, no. 14 (2023): 11692.

[87] D. Yu, X. Gao, F. Shao, et al., “Antigen-presenting Innate Lymphoid Cells Induced by BCG Vaccination Promote a respiratory Antiviral Immune Response Through the Skin‒Lung Axis,” Cellular & Molecular Immunology 22, no. 4 (2025): 390-402.

[88] K. Kang, M. Bachu, S. H. Park, et al., “IFN-γ Selectively Suppresses a Subset of TLR4-activated Genes and Enhancers to Potentiate Macrophage Activation,” Nature Communications 10, no. 1 (2019): 3320.

[89] T. R. Mosmann, A. J. McMichael, A. LeVert, J. W. McCauley, and J. W. Almond, “Opportunities and Challenges for T Cell-based Influenza Vaccines,” Nature Reviews Immunology 24, no. 10 (2024): 736-752.

[90] C. Wei, W. Jiang, R. Wang, et al., “Brain Endothelial GSDMD Activation Mediates Inflammatory BBB Breakdown,” Nature 629, no. 8013 (2024): 893-900.

[91] A. Mantovani and M. G. Netea, “Trained Innate Immunity, Epigenetics, and Covid-19,” New England Journal of Medicine 383, no. 11 (2020): 1078-1080.

[92] A. Bahl, S. Pandey, R. Rakshit, S. Kant, and D. Tripathi, “Infection-induced Trained Immunity: A Twist in Paradigm of Innate Host Defense and Generation of Immunological Memory,” Infection and Immunity 93, no. 1 (2025): e0047224.

[93] K. A. Tran, E. Pernet, M. Sadeghi, et al., “BCG Immunization Induces CX3CR1(hi) Effector Memory T Cells to Provide Cross-protection via IFN-γ-mediated Trained Immunity,” Nature Immunology 25, no. 3 (2024): 418-431.

[94] Y. Wang, Y. Li, J. Chen, et al., “Inhibition of TIGIT on NK Cells Improves Their Cytotoxicity and HIV Reservoir Eradication Potential,” MBio 16, no. 3 (2025): e0322624.

[95] A. Ziogas and M. G. Netea, “Trained Immunity-related Vaccines: Innate Immune Memory and Heterologous Protection Against Infections,” Trends in Molecular Medicine 28, no. 6 (2022): 497-512.

[96] W. Dai, X. Qiao, Y. Fang, et al., “Epigenetics-targeted Drugs: Current Paradigms and Future Challenges,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 332.

[97] M. G. Netea, J. Domínguez-Andrés, L. B. Barreiro, et al., “Defining Trained Immunity and Its Role in Health and Disease,” Nature Reviews Immunology 20, no. 6 (2020): 375-388.

[98] B. Chong, J. Jayabaskaran, S. M. Jauhari, et al., “Global Burden of Cardiovascular Diseases: Projections From 2025 to 2050,” European Journal of Preventive Cardiology (2024).

[99] M. S. Wang, J. W. Deng, W. Y. Geng, et al., “Temporal Trend and Attributable Risk Factors of Cardiovascular Disease Burden for Adults 55 Years and Older in 204 Countries/territories From 1990 to 2021: An Analysis for the Global Burden of Disease Study 2021,” European Journal of Preventive Cardiology 32, no. 7 (2025): 539-552.

[100] M. G. Netea and L. A. B. Joosten, “Trained Innate Immunity: Concept, Nomenclature, and Future Perspectives,” Journal of Allergy and Clinical Immunology 154, no. 5 (2024): 1079-1084.

[101] T. Y. Huang, M. Hirota, D. Sasaki, et al., “Phosphoenolpyruvate Regulates the Th17 Transcriptional Program and Inhibits Autoimmunity,” Cell Reports 42, no. 3 (2023): 112205.

[102] H. Huang, Q. S. Tong, J. Y. Zhang, et al., “Phagocytosis-Activating Nanocomplex Orchestrates Macrophage-Mediated Cancer Immunotherapy,” Advanced Materials 37, no. 28 (2025): e2500982.

[103] M. Gonzalez, S. Clayton, E. Wauson, D. Christian, and Q. K. Tran, “Promotion of Nitric Oxide Production: Mechanisms, Strategies, and Possibilities,” Frontiers in Physiology 16 (2025): 1545044.

[104] V. Singh, R. Kaur, P. Kumari, C. Pasricha, and R. Singh, “ICAM-1 and VCAM-1: Gatekeepers in Various Inflammatory and Cardiovascular Disorders,” Clinica Chimica Acta 548 (2023): 117487.

[105] G. Morris, M. Gevezova, V. Sarafian, and M. Maes, “Redox Regulation of the Immune Response,” Cellular & Molecular Immunology 19, no. 10 (2022): 1079-1101.

[106] P. Libby, “The Changing Landscape of Atherosclerosis,” Nature 592, no. 7855 (2021): 524-533.

[107] P. Libby, J. E. Buring, L. Badimon, et al., “Atherosclerosis,” Nature Reviews Disease Primers 5, no. 1 (2019): 56.

[108] D. Wolf and K. Ley, “Immunity and Inflammation in Atherosclerosis,” Circulation Research 124, no. 2 (2019): 315-327.

[109] B. Gigante, J. H. Levy, E. van Gorp, et al., “Management of Patients on Antithrombotic Therapy With Severe Infections: A Joint Clinical Consensus Statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and Haemostasis,” European Heart Journal 44, no. 32 (2023): 3040-3058.

[110] A. Tanasov and G. S. Tiplica, “Erectile Dysfunction in Dermatology and Venereology: From Aetiopathogenic Mechanisms to Practical Considerations for Dermato-venereologists,” Journal of the European Academy of Dermatology and Venereology 39, no. 10 (2025): 1725-1737.

[111] M. G. Netea, E. J. Giamarellos-Bourboulis, J. Domínguez-Andrés, et al., “Trained Immunity: A Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection,” Cell 181, no. 5 (2020): 969-977.

[112] A. Ziogas, B. Novakovic, L. Ventriglia, et al., “Long-term Histone Lactylation Connects Metabolic and Epigenetic Rewiring in Innate Immune Memory,” Cell 188, no. 11 (2025): 2992-3012. e16.

[113] A. Rigamonti, J. Villar, and E. Segura, “Monocyte Differentiation Within Tissues: A Renewed Outlook,” Trends in Immunology 44, no. 12 (2023): 999-1013.

[114] H. Wang, Z. Fan, P. V. Shliaha, et al., “H3K4me3 regulates RNA Polymerase II Promoter-proximal Pause-release,” Nature 615, no. 7951 (2023): 339-348.

[115] N. A. Scott, L. Pearmain, S. B. Knight, et al., “Monocyte Migration Profiles Define Disease Severity in Acute COVID-19 and Unique Features of Long COVID,” European Respiratory Journal 61, no. 5 (2023): 2202226.

[116] Y. Sohrabi, S. M. M. Lagache, V. C. Voges, et al., “OxLDL-mediated Immunologic Memory in Endothelial Cells,” Journal of Molecular and Cellular Cardiology 146 (2020): 121-132.

[117] A. Llibre, S. Kucuk, A. Gope, M. Certo, and C. Mauro, “Lactate: A Key Regulator of the Immune Response,” Immunity 58, no. 3 (2025): 535-554.

[118] S. Fanucchi, J. Domínguez-Andrés, L. A. B. Joosten, M. G. Netea, and M. M. Mhlanga, “The Intersection of Epigenetics and Metabolism in Trained Immunity,” Immunity 54, no. 1 (2021): 32-43.

[119] A. Ajoolabady, D. Pratico, L. Lin, et al., “Inflammation in Atherosclerosis: Pathophysiology and Mechanisms,” Cell Death & Disease 15, no. 11 (2024): 817.

[120] S. Yuan, R. Sun, H. Shi, et al., “VDAC2 loss Elicits Tumour Destruction and Inflammation for Cancer Therapy,” Nature 640, no. 8060 (2025): 1062-1071.

[121] X. Chu, Y. Tian, and C. Lv, “Decoding the Spatiotemporal Heterogeneity of Tumor-associated Macrophages,” Molecular Cancer 23, no. 1 (2024): 150.

[122] D. J. Kloosterman, J. Erbani, M. Boon, et al., “Macrophage-mediated Myelin Recycling Fuels Brain Cancer Malignancy,” Cell 187, no. 19 (2024): 5336-5356. e30.

[123] X. Zhang, M. Lao, K. Sun, et al., “Sphingolipid Synthesis in Tumor-associated Macrophages Confers Immunotherapy Resistance in Hepatocellular Carcinoma,” Science Advances 11, no. 21 (2025): eadv0558.

[124] Y. Li, H. Chen, Q. Yang, et al., “Increased Drp1 Promotes Autophagy and ESCC Progression by mtDNA Stress Mediated cGAS-STING Pathway,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 76.

[125] A. E. Geller, R. Shrestha, M. R. Woeste, et al., “The Induction of Peripheral Trained Immunity in the Pancreas Incites Anti-tumor Activity to Control Pancreatic Cancer Progression,” Nature Communications 13, no. 1 (2022): 759.

[126] S. Moorlag, N. Khan, B. Novakovic, et al., “β-Glucan Induces Protective Trained Immunity Against Mycobacterium Tuberculosis Infection: A Key Role for IL-1,” Cell Reports 31, no. 7 (2020): 107634.

[127] G. D. Liatsos, I. Mariolis, E. Hadziyannis, A. Bamias, and D. Vassilopoulos, “Review of BCG Immunotherapy for Bladder Cancer,” Clinical Microbiology Reviews 38, no. 1 (2025): e0019423.

[128] X. Mao, J. Xu, W. Wang, et al., “Crosstalk Between Cancer-associated Fibroblasts and Immune Cells in the Tumor Microenvironment: New Findings and Future Perspectives,” Molecular Cancer 20, no. 1 (2021): 131.

[129] L. Liu, Y. Li, and B. Li, “Interactions Between Cancer Cells and Tumor-associated Macrophages in Tumor Microenvironment,” Biochimica et Biophysica Acta: Reviews on Cancer 1880, no. 3 (2025): 189344.

[130] G. Dunsmore, W. Guo, Z. Li, et al., “Timing and Location Dictate Monocyte Fate and Their Transition to Tumor-associated Macrophages,” Science Immunology 9, no. 97 (2024): eadk3981.

[131] A. Tsuyada, A. Chow, J. Wu, et al., “CCL2 mediates Cross-talk Between Cancer Cells and Stromal Fibroblasts That Regulates Breast Cancer Stem Cells,” Cancer Research 72, no. 11 (2012): 2768-2779.

[132] T. Qiao, W. Yang, X. He, et al., “Dynamic Differentiation of F4/80+ Tumor-associated Macrophage and Its Role in Tumor Vascularization in a Syngeneic Mouse Model of Colorectal Liver Metastasis,” Cell Death & Disease 14, no. 2 (2023): 117.

[133] R. Chen, R. Kang, and D. Tang, “The Mechanism of HMGB1 Secretion and Release,” Experimental & Molecular Medicine 54, no. 2 (2022): 91-102.

[134] Q. Li, L. Zhou, L. Wang, et al., “Bcl6 modulates Innate Immunity by Controlling Macrophage Activity and Plays Critical Role in Experimental Autoimmune Encephalomyelitis,” European Journal of Immunology 50, no. 4 (2020): 525-536.

[135] M. Jiang, K. Zhang, Z. Zhang, et al., “PI3K/AKT/mTOR Axis in Cancer: From Pathogenesis to Treatment,” MedComm 6, no. 8 (2025): e70295.

[136] M. A. Franczak, O. Krol, G. Harasim, et al., “Metabolic Effects of New Glucose Transporter (GLUT-1) and Lactate Dehydrogenase-A (LDH-A) Inhibitors Against Chemoresistant Malignant Mesothelioma,” International Journal of Molecular Sciences 24, no. 9 (2023): 7771.

[137] E. R. Adelman, H. T. Huang, A. Roisman, et al., “Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia,” Cancer Discovery 9, no. 8 (2019): 1080-1101.

[138] D. B. Stamos, L. M. Clubb, and A. Mitra, “The Histone Demethylase Lsd1 Regulates Multiple Repressive Gene Programs During T Cell Development,” Journal of Experimental Medicine 218, no. 12 (2021): e20202012.

[139] W. Zhang, Q. Han, Y. Ding, et al., “Bcl6 drives Stem-Like Memory Macrophages Differentiation to Foster Tumor Progression,” Cellular and Molecular Life Sciences 80, no. 1 (2022): 14.

[140] Q. Yang, N. Guo, Y. Zhou, J. Chen, Q. Wei, and M. Han, “The Role of Tumor-associated Macrophages (TAMs) in Tumor Progression and Relevant Advance in Targeted Therapy,” Acta Pharmaceutica Sinica B 10, no. 11 (2020): 2156-2170.

[141] R. Mohebi, Y. Liu, M. K. Hansen, et al., “Associations of Angiopoietin 2 and Vascular Endothelial Growth Factor-A Concentrations With Clinical End Points,” Clinical Journal of the American Society of Nephrology 19, no. 4 (2024): 429-437.

[142] M. M. Steele, A. Jaiswal, I. Delclaux, et al., “T Cell Egress via Lymphatic Vessels Is Tuned by Antigen Encounter and Limits Tumor Control,” Nature Immunology 24, no. 4 (2023): 664-675.

[143] I. Henderson, R. Lynch, S. Gerry, J. McLeish, P. Watkinson, and M. Knight, “Severe Maternal Morbidity in the High Income Setting: A Systematic Review of Composite Definitions,” EClinicalMedicine 81 (2025): 103105.

[144] C. Ding, R. Shrestha, X. Zhu, et al., “Inducing Trained Immunity in Pro-metastatic Macrophages to Control Tumor Metastasis,” Nature Immunology 24, no. 2 (2023): 239-254.

[145] M. Yadav, A. Sharma, K. Patne, et al., “AXL Signaling in Cancer: From Molecular Insights to Targeted Therapies,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 37.

[146] P. Vuscan, B. Kischkel, L. A. B. Joosten, and M. G. Netea, “Microbial-induced Trained Immunity for Cancer Immunotherapy,” Pharmacological Reviews 77, no. 5 (2025): 100074.

[147] L. Minute, K. Montalbán-Hernández, L. Bravo-Robles, L. Conejero, S. Iborra, and C. Del Fresno, “Trained Immunity-based Mucosal Immunotherapies for the Prevention of respiratory Infections,” Trends in Immunology 46, no. 4 (2025): 270-283.

[148] J. Chronopoulos, M. Crespo, and T. Chavakis, “Central Trained Immunity in the Context of Bladder Cancer Immunotherapy,” Cancer Cell 43, no. 8 (2025): 1394-1396.

[149] O. Pail, M. J. Lin, T. Anagnostou, B. D. Brown, and J. D. Brody, “Cancer Vaccines and the Future of Immunotherapy,” Lancet 406, no. 10499 (2025): 189-202.

[150] A. Ziogas, M. Bruno, R. van der Meel, W. J. M. Mulder, and M. G. Netea, “Trained Immunity: Target for Prophylaxis and Therapy,” Cell Host & Microbe 31, no. 11 (2023): 1776-1791.

[151] B. A. Blok, R. J. W. Arts, R. van Crevel, et al., “Differential Effects of BCG Vaccine on Immune Responses Induced by vi Polysaccharide Typhoid Fever Vaccination: An Explorative Randomized Trial,” European Journal of Clinical Microbiology & Infectious Diseases 39, no. 6 (2020): 1177-1184.

[152] H. Cai, X. Chen, Y. Liu, et al., “Lactate Activates Trained Immunity by Fueling the Tricarboxylic Acid Cycle and Regulating Histone Lactylation,” Nature Communications 16, no. 1 (2025): 3230.

[153] R. J. Arts, B. A. Blok, P. Aaby, et al., “Long-term in Vitro and in Vivo Effects of γ-irradiated BCG on Innate and Adaptive Immunity,” Journal of Leukocyte Biology 98, no. 6 (2015): 995-1001.

[154] S. Moorlag, R. J. W. Arts, R. van Crevel, and M. G. Netea, “Non-specific Effects of BCG Vaccine on Viral Infections,” Clinical Microbiology and Infection 25, no. 12 (2019): 1473-1478.

[155] S. Moorlag, E. Taks, T. Ten Doesschate, et al., “Efficacy of BCG Vaccination against Respiratory Tract Infections in Older Adults during the Coronavirus Disease 2019 Pandemic,” Clinical Infectious Diseases 75, no. 1 (2022): e938-e946.

[156] T. N. Nissen, N. M. Birk, G. Smits, et al., “Bacille Calmette-Guérin (BCG) Vaccination at Birth and Antibody Responses to Childhood Vaccines. A Randomised Clinical Trial,” Vaccine 35, no. 16 (2017): 2084-2091.

[157] L. C. J. de Bree, R. J. Marijnissen, J. M. Kel, et al., “Bacillus Calmette-Guérin-Induced Trained Immunity Is Not Protective for Experimental Influenza A/Anhui/1/2013 (H7N9) Infection in Mice,” Frontiers in Immunology 9 (2018): 869.

[158] E. J. Giamarellos-Bourboulis, M. Tsilika, S. Moorlag, et al., “Activate: Randomized Clinical Trial of BCG Vaccination Against Infection in the Elderly,” Cell 183, no. 2 (2020): 315-323. e9.

[159] N. A. Brooks, V. Narayan, P. K. Hegarty, H. Zafirakis, X. Y. Han, and A. M. Kamat, “The Role of the Urologist, BCG Vaccine Administration, and SARS-CoV-2: An Overview,” BJUI Compass 1, no. 3 (2020): 87-92.

[160] A. R. DiNardo, M. Arditi, A. M. Kamat, et al., “Bacillus Calmette-Guérin Vaccination as Defense Against SARS-CoV-2 (BADAS): A Randomized Controlled Trial to Protect Healthcare Workers in the USA by Enhanced Trained Immune Responses,” Trials 24, no. 1 (2023): 636.

[161] K. Föhse, E. J. M. Taks, S. Moorlag, et al., “The Impact of Circadian Rhythm on Bacillus Calmette-Guérin Vaccination Effects on SARS-CoV-2 Infections,” Frontiers in Immunology 14 (2023): 980711.

[162] E. J. Giamarellos-Bourboulis, A. C. Aschenbrenner, M. Bauer, et al., “The Pathophysiology of Sepsis and Precision-medicine-based Immunotherapy,” Nature Immunology 25, no. 1 (2024): 19-28.

[163] L. Pierneef, A. van Hooij, D. de Jong, et al., “Rapid Test for Mycobacterium Leprae Infection: A Practical Tool for Leprosy,” Infectious Diseases of Poverty Home 13, no. 1 (2024): 88.

[164] T. Ten Doesschate, S. Moorlag, T. W. van der Vaart, et al., “Two Randomized Controlled Trials of Bacillus Calmette-Guérin Vaccination to Reduce Absenteeism Among Health Care Workers and Hospital Admission by Elderly Persons During the COVID-19 Pandemic: A Structured Summary of the Study Protocols for Two Randomised Controlled Trials,” Trials 21, no. 1 (2020): 481.

[165] R. A. de Souza, F. R. Barreto, C. C. O. de Jesus Lima, et al., “Efficacy of BCG Vaccination on Incidence, Severity and Clinical Progression of COVID-19: A BCG-REVAC Population Analysis,” Vaccine 54 (2025): 126911.

[166] M. C. Noverr, J. Yano, M. E. Hagensee, et al., “Effect of MMR Vaccination to Mitigate Severe Sequelae Associated with COVID-19: Challenges and Lessons Learned,” Medical Research Archives 11, no. 2 (2023): 3598.

[167] K. Chumakov, M. S. Avidan, C. S. Benn, et al., “Old Vaccines for New Infections: Exploiting Innate Immunity to Control COVID-19 and Prevent Future Pandemics,” Proceedings of the National Academy of Sciences of the United States of America 118, no. 21 (2021): e2101718118.

[168] A. Y. Chang, P. Aaby, M. S. Avidan, et al., “One Vaccine to Counter Many Diseases? Modeling the Economics of Oral Polio Vaccine Against Child Mortality and COVID-19,” Frontiers in Public Health 10 (2022): 967920.

[169] M. Partinen, B. Holzinger, C. M. Morin, et al., “Sleep and Daytime Problems During the COVID-19 Pandemic and Effects of Coronavirus Infection, Confinement and Financial Suffering: A Multinational Survey Using a Harmonised Questionnaire,” BMJ Open 11, no. 12 (2021): e050672.

[170] I. Wagenhäuser, J. Reusch, A. Gabel, et al., “Immunogenicity and Safety of Coadministration of COVID-19 and Influenza Vaccination,” European Respiratory Journal 61, no. 1 (2023): 2201390.

[171] G. Almanzar, K. Koosha, T. Vogt, et al., “Hybrid Immunity by Two COVID-19 mRNA Vaccinations and One Breakthrough Infection Provides a Robust and Balanced Cellular Immune Response as Basic Immunity Against Severe Acute respiratory Syndrome Coronavirus 2,” Journal of Medical Virology 96, no. 6 (2024): e29739.

[172] L. E. van Eekeren, Q. de Mast, E. M. G. Meeder, et al., “Plasma Proteomic Signatures of Liver Steatosis and Fibrosis in People Living With HIV: A Cross-sectional Study,” EBioMedicine 109 (2024): 105407.

[173] J. A. Harper, C. South, M. H. Trivedi, and M. S. Toups, “Pilot Investigation Into the Sickness Response to Influenza Vaccination in Adults: Effect of Depression and Anxiety,” General Hospital Psychiatry 48 (2017): 56-61.

[174] A. R. Azab, R. K. Elnaggar, D. G. Hamouda, et al., “Respiratory and Functional Benefits of Manual Diaphragmatic Release for Cleaning-laborers Exposed to Occupational Hazards,” Physiotherapy Research International 29, no. 4 (2024): e70001.

[175] N. Nourie, C. Boueri, H. Tran Minh, et al., “BK Polyomavirus Infection in Kidney Transplantation: A Comprehensive Review of Current Challenges and Future Directions,” International Journal of Molecular Sciences 25, no. 23 (2024): 12801.

[176] L. M. Nanque, A. Varma, S. M. Thysen, et al., “Effect of a Campaign With Oral Polio Vaccine on General Health: A Cluster-randomised Trial in Rural Guinea-Bissau,” Journal of Infection 89, no. 6 (2024): 106302.

[177] N. I. Shapiro, M. R. Filbin, P. C. Hou, et al., “Diagnostic Accuracy of a Bacterial and Viral Biomarker Point-of-Care Test in the Outpatient Setting,” JAMA Network Open 5, no. 10 (2022): e2234588.

[178] Y. T. Pinilla, S. T. Boussougou-Sambe, S. Gräßle, et al., “Experimental Transmission of Plasmodium Malariae to Anopheles Gambiae,” Journal of Infectious Diseases 223, no. 3 (2021): 522-526.

[179] J. van Tuijl, J. I. P. van Heck, H. Bahrar, et al., “Single High-fat Challenge and Trained Innate Immunity: A Randomized Controlled Cross-Over Trial,” Iscience 27, no. 11 (2024): 111103.

[180] M. P. Noz, S. Bekkering, L. Groh, et al., “Reprogramming of Bone Marrow Myeloid Progenitor Cells in Patients With Severe Coronary Artery Disease,” Elife 9 (2020): e60939.

[181] L. Räber, Y. Ueki, T. Otsuka, et al., “Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients with Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial,” Jama 327, no. 18 (2022): 1771-1781.

[182] S. Bekkering, R. J. W. Arts, B. Novakovic, et al., “Metabolic Induction of Trained Immunity Through the Mevalonate Pathway,” Cell 172, no. 1-2 (2018): 135-146. e9.

[183] L. A. Groh, L. H. Willems, P. Fintelman, M. Reijnen, S. El Messaoudi, and M. C. Warlé, “Dual-Pathway Inhibition With Rivaroxaban and Low-Dose Aspirin Does Not Alter Immune Cell Responsiveness and Distribution in Patients With Coronary Artery Disease,” Cardiol Therapeutics 13, no. 1 (2024): 233-242.

[184] M. Yu, Z. F. Zhu, F. Yang, et al., “Different Anti-inflammatory Drugs on High-Sensitivity C-Reactive Protein in Patients after Percutaneous Coronary Intervention: A Pilot Randomized Clinical Trial,” Journal of Cardiovascular Pharmacology 83, no. 3 (2024): 234-242.

[185] M. Yu, Y. Yang, S. L. Dong, et al., “Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial,” Circulation 150, no. 13 (2024): 981-993.

[186] Q. Wang, W. Ma, D. Zhang, et al., “Effectiveness and Safety of a Novel Intravascular Lithotripsy System for Severe Coronary Calcification: The CALCI-CRACK Trial,” Canadian Journal of Cardiology 40, no. 9 (2024): 1657-1667.

[187] P. Brandi, L. Conejero, F. J. Cueto, et al., “Trained Immunity Induction by the Inactivated Mucosal Vaccine MV130 Protects Against Experimental Viral respiratory Infections,” Cell Reports 38, no. 1 (2022): 110184.

[188] J. Zwaag, R. Naaktgeboren, A. E. van Herwaarden, P. Pickkers, and M. Kox, “The Effects of Cold Exposure Training and a Breathing Exercise on the Inflammatory Response in Humans: A Pilot Study,” Psychosomatic Medicine 84, no. 4 (2022): 457-467.

[189] M. A. Wefers Bettink, J. Zwaag, B. Schockaert, P. Pickkers, M. Kox, and E. G. Mik, “Measuring Mitochondrial Oxygenation and Respiration During Systemic Inflammation in Humans in Vivo,” Scientific Reports 15, no. 1 (2025): 25815.

[190] T. T. Tang, Y. Song, Y. J. Ding, et al., “Atorvastatin Upregulates Regulatory T Cells and Reduces Clinical Disease Activity in Patients With Rheumatoid Arthritis,” Journal of Lipid Research 52, no. 5 (2011): 1023-1032.

[191] R. Furie, J. Steffgen, N. Fagan, et al., “Two-year Treatment Experience With BI 655064, an Antagonistic Anti-CD40 Antibody, in Patients With Active Lupus Nephritis: An Exploratory, Phase II Maintenance Trial,” Lupus 34, no. 5 (2025): 460-473.

[192] C. V. M. Sarmento, S. Moon, T. Pfeifer, et al., “The Therapeutic Efficacy of Qigong Exercise on the Main Symptoms of Fibromyalgia: A Pilot Randomized Clinical Trial,” Integrative Medicine Research 9, no. 4 (2020): 100416.

[193] A. Cambriel, A. Tsai, B. Choisy, et al., “Immune Modulation by Personalized vs. Standard Prehabilitation before Major Surgery: A Randomized Controlled Trial,” Medrxiv (2025).

[194] F. Zoulim, O. Lenz, J. J. Vandenbossche, et al., “JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients with Chronic Infection,” Gastroenterology 159, no. 2 (2020): 521-533. e9.

[195] J. H. Stone, A. Khosroshahi, W. Zhang, et al., “Inebilizumab for Treatment of IgG4-Related Disease,” New England Journal of Medicine 392, no. 12 (2025): 1168-1177.

[196] J. Koshiol, F. Castro, T. J. Kemp, et al., “Association of Inflammatory and Other Immune Markers With Gallbladder Cancer: Results From Two Independent Case-control Studies,” Cytokine 83 (2016): 217-225.

[197] L. Martinez, O. Cords, Q. Liu, et al., “Infant BCG Vaccination and Risk of Pulmonary and Extrapulmonary Tuberculosis throughout the Life Course: A Systematic Review and Individual Participant Data Meta-analysis,” The Lancet Global Health 10, no. 9 (2022): e1307-e1316.

[198] A. Wilson and C. McCormick, “Reticulophagy and Viral Infection,” Autophagy 21, no. 1 (2025): 3-20.

[199] N. K. Björkström, B. Strunz, and H.-G. Ljunggren, “Natural Killer Cells in Antiviral Immunity,” Nature Reviews Immunology 22, no. 2 (2022): 112-123.

[200] S. J. Hofer, S. Rapp, P. Klenerman, and A. K. Simon, “Understanding and Improving Vaccine Efficacy in Older Adults,” Nature Aging 5, no. 8 (2025): 1455-1470.

[201] S. Pal, Z. Rafiq, R. Kumari, et al. Trained Innate Immunity. In: Kishore U, George AJT, eds. Innate Immunity: Pattern Recognition and Effector Mechanism (Springer Nature Switzerland, 2025): 275-296.

[202] S. Li, Y. Zou, A. McMasters, F. Chen, and J. Yan, “Trained Immunity: A New Player in Cancer Immunotherapy,” Elife 14 (2025): e104920.

[203] M. Tekguc, J. B. Wing, M. Osaki, J. Long, and S. Sakaguchi, “Treg-expressed CTLA-4 Depletes CD80/CD86 by Trogocytosis, Releasing Free PD-L1 on Antigen-presenting Cells,” Proceedings of the National Academy of Sciences of the United States of America 118, no. 30 (2021): e2023739118.

[204] K. Peng, X. Zhao, Y. X. Fu, and Y. Liang, “Eliciting Antitumor Immunity via Therapeutic Cancer Vaccines,” Cellular & Molecular Immunology 22, no. 8 (2025): 840-868.

[205] F. Peyraud, J. P. Guégan, C. Rey, et al., “Spatially Resolved Transcriptomics Reveal the Determinants of Primary Resistance to Immunotherapy in NSCLC With Mature Tertiary Lymphoid Structures,” Cell Reports Medicine 6, no. 2 (2025): 101934.

[206] P. Icard, M. Prieto, A. Coquerel, et al., “Why and How Citrate May Sensitize Malignant Tumors to Immunotherapy,” Drug Resistance Updates 78 (2025): 101177.

[207] H. Chen, J. Song, L. Zeng, et al., “Dietary Sodium Modulates mTORC1-dependent Trained Immunity in Macrophages to Accelerate CKD Development,” Biochemical Pharmacology 229 (2024): 116505.

[208] R. S. Laureano, J. Sprooten, I. Vanmeerbeerk, et al., “Trial Watch: Dendritic Cell (DC)-based Immunotherapy for Cancer,” Oncoimmunology 11, no. 1 (2022): 2096363.

[209] P. D. Katsikis, K. J. Ishii, and C. Schliehe, “Challenges in Developing Personalized Neoantigen Cancer Vaccines,” Nature Reviews Immunology 24, no. 3 (2024): 213-227.

[210] M. Wang, Y. He, Z. Zhong, et al., “Histone H3 Lysine 4 Methylation Recruits DNA Demethylases to Enforce Gene Expression in Arabidopsis,” Nature Plants 11, no. 2 (2025): 206-217.

[211] L. Chan, K. Pinedo, M. A. Stabile, et al., “Prior Vaccination Prevents Overactivation of Innate Immune Responses During COVID-19 Breakthrough Infection,” Science Translational Medicine 17, no. 783 (2025): eadq1086.

[212] Q. Zhang and L. Si, “Live Vaccine Development Through Targeted Protein Degradation,” Nature Reviews Immunology 25, no. 9 (2025): 633.

[213] N. Todosenko, O. Khaziakhmatova, V. Malashchenko, et al., “Adipocyte- and Monocyte-Mediated Vicious Circle of Inflammation and Obesity (Review of Cellular and Molecular Mechanisms),” International Journal of Molecular Sciences 24, no. 15 (2023): 12259.

[214] V. Radushev, I. Karkossa, J. Berg, et al., “Dysregulated Cytokine and Oxidative Response in Hyper-glycolytic Monocytes in Obesity,” Frontiers in Immunology 15 (2024): 1416543.

[215] K. Murata, N. Nakao, N. Ishiuchi, et al., “Four Cases of Cytokine Storm After COVID-19 Vaccination: Case Report,” Frontiers in Immunology 13 (2022): 967226.

[216] Z. Hu, S. H. Lu, D. B. Lowrie, and X. Y. Fan, “Trained Immunity: A Yin-Yang Balance,” MedComm 3, no. 1 (2022): e121.

[217] N. Lam, Y. Lee, and D. L. Farber, “A Guide to Adaptive Immune Memory,” Nature Reviews Immunology 24, no. 11 (2024): 810-829.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.